Allergen immunotherapy

Curex Revolutionizing Allergy Immunotherapy with Telehealth and Home-Delivered Allergy Drops

Retrieved on: 
Thursday, December 28, 2023
Online, Immunotherapy, Travel, Allergen, Allergen immunotherapy, Pharmacy, Collection, Allergy, Cat, Research, Pain, Pharmacist, Tongue, MITES, Dog, Insurance, Patient, Dust, Vaccine

Online allergy clinic, Curex, is transforming how allergies are treated in the US with its affordable convenient alternative to allergy shots.

Key Points: 
  • Online allergy clinic, Curex, is transforming how allergies are treated in the US with its affordable convenient alternative to allergy shots.
  • However, conventional allergy immunotherapy often involves frequent in-person visits to an allergist's office, adding a time-consuming and inconvenient aspect to the treatment.
  • Studies have shown that up to 75% of allergy sufferers discontinue allergy shots due to these challenges.
  • Allergy sufferers seeking relief through Curex must first share some details about their symptoms, allowing Curex’s doctors to facilitate an allergy test.

Insights on the Allergy Immunotherapy Global Market to 2028 - Featuring HAL Allergy, Aimmune Therapeutics and DBV Technologies Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 26, 2022
Health, Pharmaceutical, Immunotherapy, Allergen immunotherapy, Allergic rhinitis, Allergy, Marketing, Asthma, MITES, CAGR, Region, Growth, US, Sublingual administration, Food allergy, Industry, SCIT, Market share, Retail

The "Allergy Immunotherapy Market, by Treatment Type, by Allergy Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Allergy Immunotherapy Market, by Treatment Type, by Allergy Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • Immunotherapy is a preventive treatment for allergic reaction to substance such as grass pollens, house dust mites, and bee venom.
  • Subcutaneous immunotherapy (SCIT) and Sublingual immunotherapy (SLIT) are the immunotherapies used for the treatment of allergic rhinitis, allergic asthma, food allergy, venom allergy, and other allergies.
  • The global allergy immunotherapy market is expected to witness significant growth over the forecast period, owing to increasing approval of allergy immunotherapy by regulatory authority.

Intrommune Therapeutics Presents at Next Generation Food Allergy Drug Summit

Retrieved on: 
Thursday, July 22, 2021
Medical specialties, Clinical medicine, Medicine, Food allergies, Immune system, Immunology, Allergology, Allergy, Allergen immunotherapy, Immunotherapy, Kari Nadeau, Allergies in dogs

NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics , a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is participating in the Next Generation Food Allergy Drug Summit.

Key Points: 
  • NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics , a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is participating in the Next Generation Food Allergy Drug Summit.
  • Dr. Reisacher is also the inventor of oral mucosal immunotherapy (OMIT) and is a Senior Scientific Advisor to Intrommune Therapeutics.
  • Success with allergy immunotherapy hinges on consistent exposure of a patients immune system to gradually desensitize the patient to the specific allergy trigger over time.
  • Intrommune , dedicated to improving and protecting the lives of people with food allergy, is developing the revolutionary oral mucosal immunotherapy (OMIT) treatment platform for food allergies.

Stallergenes Greer Showcases Precision Medicine at 2021 EAACI Congress

Retrieved on: 
Sunday, July 11, 2021
Oncology, Health, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Immunology, Medicine, Allergology, Stallergenes Greer, Allergen immunotherapy, Personalized medicine, European Academy of Allergy and Clinical Immunology, Ait, Allergen, Precision medicine, Allergy

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), announces that the company showcased its advancements in precision medicine in AIT via a company sponsored symposium entitled Supporting individual patients needs: AIT still an unmatched model of personalized medicine for allergy at the European Academy of Allergy and Clinical Immunology (EAACI) 2021 Congress in Krakow (Poland).

Key Points: 
  • Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), announces that the company showcased its advancements in precision medicine in AIT via a company sponsored symposium entitled Supporting individual patients needs: AIT still an unmatched model of personalized medicine for allergy at the European Academy of Allergy and Clinical Immunology (EAACI) 2021 Congress in Krakow (Poland).
  • Stallergenes Greer is present at the congress from July 10 to July 12 and will also present nine posters addressing precision medicine in AIT and announcing new data from clinical trials and real-world studies.
  • Precision medicine is paving the way to the future of allergen immunotherapy by exploring the mechanism of disease of each individual to provide patients with precise, personalised and targeted treatment approaches.
  • Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).

Stallergenes Greer and Alyatec Announce Research Collaboration to Advance Precision Medicine in Allergen Immunotherapy

Retrieved on: 
Friday, July 9, 2021
Health, Infectious diseases, Clinical trials, Research, Pharmaceutical, Science, Medical specialties, Allergology, Medicine, Clinical medicine, Stallergenes Greer, Ait, Allergen immunotherapy, Precision medicine

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), and Alyatec, a contract research organisation based in Strasbourg University Hospital (France), today announced that they have entered into a collaboration to advance precision medicine in AIT.

Key Points: 
  • Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), and Alyatec, a contract research organisation based in Strasbourg University Hospital (France), today announced that they have entered into a collaboration to advance precision medicine in AIT.
  • This research collaboration brings together the longstanding expertise of Stallergenes Greer in AIT and Alyatecs competencies in research and clinical services as well as its state-of-the-art technology, including a new generation environmental exposure chamber.
  • We are excited about the collaboration with Alyatec which will support Stallergenes Greers ambition to advance the practice of allergology.
  • This collaboration is a remarkable opportunity for Alyatec to develop precision medicine in AIT.

WellNow Allergy Launches to Bring Convenience and Flexibility to Allergy Testing and Immunotherapy

Retrieved on: 
Tuesday, July 6, 2021
Medical specialties, Immunology, Clinical medicine, Allergology, Immune system, Allergy, Allergen immunotherapy, WellNow Urgent Care

Buffalo, NY, July 06, 2021 (GLOBE NEWSWIRE) -- WellNow Allergy , an affiliate of leading urgent care provider WellNow Urgent Care , is now accepting patients in Western New York to provide allergy sufferers of all ages with convenient, on-demand access to allergy testing and immunotherapy (also known as allergy shots).

Key Points: 
  • Buffalo, NY, July 06, 2021 (GLOBE NEWSWIRE) -- WellNow Allergy , an affiliate of leading urgent care provider WellNow Urgent Care , is now accepting patients in Western New York to provide allergy sufferers of all ages with convenient, on-demand access to allergy testing and immunotherapy (also known as allergy shots).
  • Follow-up allergy shots, if needed, can be scheduled at any of WellNow Urgent Cares seventeen locations in Western New York.
  • Theres a clear need for better access, convenience and ease when it comes to allergy diagnosis and treatment.
  • WellNow Allergy, an affiliate of WellNow Urgent Care, is a growing provider of convenient, high quality allergy care, with two allergy centers and seventeen allergy immunotherapy locations in New York.

Stallergenes Greer: Alustal®, the Company’s Subcutaneous Allergen Immunotherapy Treatment (SCIT) Now Available

Retrieved on: 
Thursday, June 24, 2021
Oncology, Health, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Immunology, Clinical medicine, Allergology, Stallergenes Greer, SCIT, Allergen immunotherapy, Allergen, Allergy, Immunotherapy, HAL Allergy Group

Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces that Alustal, its subcutaneous allergen immunotherapy (SCIT) solution, is now available in Italy and Spain following the full resumption of SCIT production in Antony (France).

Key Points: 
  • Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces that Alustal, its subcutaneous allergen immunotherapy (SCIT) solution, is now available in Italy and Spain following the full resumption of SCIT production in Antony (France).
  • Alustal will be also available in Australia, France and Switzerland in the coming months.
  • View the full release here: https://www.businesswire.com/news/home/20210624005500/en/
    We are pleased that patients and the medical community have access to an alternative allergen immunotherapy option with Alustal.
  • Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services.

Trading update

Retrieved on: 
Thursday, June 24, 2021
Allergen immunotherapy, Allergology, Immunotherapy

Some phasing of R&D and commercial costs expected to be carried over into 2022

Key Points: 
  • Some phasing of R&D and commercial costs expected to be carried over into 2022
    24 June 2021 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapy, today announces a pre-close trading update for the year ended 30 June 2021.
  • The Group plans to announce its post year end trading update on 14 July 2021 and the audited preliminary results on 23 September 2021.
  • The Groups cash position at the year-end is also expected to be strong and greater than at the prior year end.
  • This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.

Positive Outcome of European Decentralised Registration Procedure for Stallergenes Greer’s Sublingual House Dust Mite Allergen Immunotherapy Tablet

Retrieved on: 
Monday, May 31, 2021
Health, Other Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Medical specialties, Immunology, Clinical medicine, Allergology, Stallergenes Greer, Allergen immunotherapy, Allergic rhinitis, Allergen, Allergy, Immunotherapy, Rhinitis, House dust mite, the STAGR320 Clinical Trial, Allergic Rhinitis and STAGR320, THE STAGR320 CLINICAL TRIAL, ALLERGIC RHINITIS AND STAGR320

Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces the positive outcome of the European decentralised registration procedure for its sublingual house dust mite (HDM) allergen immunotherapy tablet Actair.

Key Points: 
  • Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces the positive outcome of the European decentralised registration procedure for its sublingual house dust mite (HDM) allergen immunotherapy tablet Actair.
  • Stallergenes Greer offers a wide range of treatment options and is paving the way for personalised precision medicine-based allergen immunotherapy: tablet and liquid sublingual solutions as well as subcutaneous formulations.
  • The randomised, double-blind, placebo-controlled trial was the largest Phase III clinical trial conducted to evaluate the treatment of house dust mite allergy1.
  • STAGR320 is Stallergenes Greers sublingual allergen immunotherapy (AIT) tablet for the treatment of HDM-induced allergic rhinitis.

USA Equities Corp. Reports First Quarter 2021 Financial Results and Announces Upcoming Presentation at the University of Miami

Retrieved on: 
Tuesday, May 18, 2021
Medical specialties, Clinical medicine, Medicine, Immune system, Immunology, Allergology, Allergy, Allergen immunotherapy, Allergen, Immunotherapy

\xe2\x80\x9cOn a sequential basis, our revenue more than doubled to approximately $304,000, while gross margin improved 370 basis points to 43.9%.

Key Points: 
  • \xe2\x80\x9cOn a sequential basis, our revenue more than doubled to approximately $304,000, while gross margin improved 370 basis points to 43.9%.
  • We also announced the appointment of Michael Mangus to our advisory and physician network development team.
  • For example, in March, five of our medical advisory board members presented at the inaugural University of Miami Allergy Diagnostics and Allergen Immunotherapy Virtual CME event.
  • Our team will also participate in a similar workshop at the University of Miami\xe2\x80\x99s Miller School of Medicine on June 26, 2021.